Nektar Therapeutics Highlights from Q4 2025 Earnings Call
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NKTR?
Source: seekingalpha
- Clinical Progress of REZPEG: Nektar Therapeutics reported positive results from Phase IIb studies of REZPEG for atopic dermatitis and alopecia areata in Q4 2025, with significant increases in EASI-75 and EASI-90 scores, indicating its potential in treating inflammatory diseases and positioning the company favorably in a narrowing competitive landscape.
- Strong Financial Position: By the end of 2025, the company had $245.8 million in cash and investments with no debt, and subsequently raised approximately $476 million in net cash, providing ample funding for the upcoming Phase III trials, with expectations to end 2026 with $400 million to $460 million in cash and investments.
- Revenue and Expense Overview: The company reported $21.8 million in revenue for Q4 2025 and $55.2 million for the full year, despite a net loss of $36.1 million, reflecting ongoing investments in R&D and marketing, with projected R&D expenses for 2026 expected to be between $200 million and $250 million.
- Market Outlook and Strategy: Management expressed confidence in REZPEG's unique efficacy and safety profile, planning to initiate Phase III trials in June 2026, emphasizing REZPEG's differentiated competitive advantage in the atopic dermatitis market, which is expected to drive future market share growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 73.330
Low
102.00
Averages
123.43
High
165.00
Current: 73.330
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Highlights from Q4 2025 Earnings Call
- Clinical Progress of REZPEG: Nektar Therapeutics reported positive results from Phase IIb studies of REZPEG for atopic dermatitis and alopecia areata in Q4 2025, with significant increases in EASI-75 and EASI-90 scores, indicating its potential in treating inflammatory diseases and positioning the company favorably in a narrowing competitive landscape.
- Strong Financial Position: By the end of 2025, the company had $245.8 million in cash and investments with no debt, and subsequently raised approximately $476 million in net cash, providing ample funding for the upcoming Phase III trials, with expectations to end 2026 with $400 million to $460 million in cash and investments.
- Revenue and Expense Overview: The company reported $21.8 million in revenue for Q4 2025 and $55.2 million for the full year, despite a net loss of $36.1 million, reflecting ongoing investments in R&D and marketing, with projected R&D expenses for 2026 expected to be between $200 million and $250 million.
- Market Outlook and Strategy: Management expressed confidence in REZPEG's unique efficacy and safety profile, planning to initiate Phase III trials in June 2026, emphasizing REZPEG's differentiated competitive advantage in the atopic dermatitis market, which is expected to drive future market share growth.
See More
Nektar (NKTR) Q4 2025 Earnings Call Transcript
See More
Faruqi & Faruqi Investigates Nektar Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Nektar Therapeutics, focusing on investors who purchased securities between February 26, 2025, and December 15, 2025, indicating a commitment to protecting investor rights.
- Investor Contact Information: The firm encourages affected investors to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating their dedication to supporting investors.
- Class Action Deadline: Faruq & Faruqi reminds investors that the deadline to seek lead plaintiff status in the federal securities class action against Nektar is May 5, 2026, highlighting the importance of timely action to safeguard legal rights.
- Role of Securities Law Firm: As a leading national securities law firm, the investigation by Faruq & Faruqi suggests that Nektar may face legal challenges, which could impact its stock price and market confidence, prompting investors to stay alert for further developments.
See More
Class Action Reminder for Nektar Therapeutics Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that a class action has been filed, alleging the company failed to disclose the true prospects of the REZOLVE-AA trial, potentially leading to investor losses.
- Trial Issues: The complaint states that Nektar did not follow applicable instructions and protocol standards in the REZOLVE-AA trial, resulting in an overstated integrity and prospects of the trial, which undermines investor confidence in the company's future.
- Stock Price Impact: On December 16, 2025, Nektar announced that the REZOLVE-AA trial failed to achieve statistical significance, causing its stock price to drop by $4.14, or 7.77%, closing at $49.16 per share, reflecting market disappointment in the company's outlook.
- Investor Action: Robbins LLP encourages shareholders to participate in the class action, where lead plaintiffs can represent other members in the litigation, and investors do not need to participate in the case to be eligible for recovery, highlighting potential governance issues within the company.
See More
Nektar Therapeutics to Announce Q4 Earnings on March 12
- Earnings Announcement Schedule: Nektar Therapeutics is set to announce its Q4 earnings on March 12 after market close, with consensus EPS estimate at -$2.47 and revenue estimate at $10.41 million, reflecting a significant 64.3% year-over-year decline, indicating substantial revenue pressure on the company.
- Historical Performance Review: Over the past two years, Nektar has only beaten EPS estimates 38% of the time and revenue estimates 63% of the time, highlighting considerable volatility in its performance and suggesting that investors should approach future results with caution.
- Estimate Revision Status: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, with revenue estimates also seeing no upward revisions and one downward revision, indicating a lack of confidence in the company's future profitability.
- Financing Activities: Nektar recently completed a $400 million stock offering, and its stock surged following a $300 million equity offering, reflecting a positive market response to its financing activities, although its overall financial health remains a concern.
See More
Nektar Therapeutics Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: A shareholder has filed a class action lawsuit on behalf of investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, alleging misrepresentations regarding the Phase 2b trial for REZOLVE-AA, which may have led to investor losses.
- Lawsuit Details Revealed: The lawsuit, initiated by Bernstein Liebhard LLP, requires investors wishing to serve as lead plaintiffs to file necessary documents by May 5, 2026, indicating their representative status in the litigation.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, showcasing its significant influence in the legal field.
- Transparent Fee Structure: All representation in this lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses, ensuring minimal financial burden for all investors participating in the litigation.
See More
Nektar Therapeutics Highlights from Q4 2025 Earnings Call
- Clinical Progress of REZPEG: Nektar Therapeutics reported positive results from Phase IIb studies of REZPEG for atopic dermatitis and alopecia areata in Q4 2025, with significant increases in EASI-75 and EASI-90 scores, indicating its potential in treating inflammatory diseases and positioning the company favorably in a narrowing competitive landscape.
- Strong Financial Position: By the end of 2025, the company had $245.8 million in cash and investments with no debt, and subsequently raised approximately $476 million in net cash, providing ample funding for the upcoming Phase III trials, with expectations to end 2026 with $400 million to $460 million in cash and investments.
- Revenue and Expense Overview: The company reported $21.8 million in revenue for Q4 2025 and $55.2 million for the full year, despite a net loss of $36.1 million, reflecting ongoing investments in R&D and marketing, with projected R&D expenses for 2026 expected to be between $200 million and $250 million.
- Market Outlook and Strategy: Management expressed confidence in REZPEG's unique efficacy and safety profile, planning to initiate Phase III trials in June 2026, emphasizing REZPEG's differentiated competitive advantage in the atopic dermatitis market, which is expected to drive future market share growth.
See More
Nektar (NKTR) Q4 2025 Earnings Call Transcript
See More
Faruqi & Faruqi Investigates Nektar Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Nektar Therapeutics, focusing on investors who purchased securities between February 26, 2025, and December 15, 2025, indicating a commitment to protecting investor rights.
- Investor Contact Information: The firm encourages affected investors to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating their dedication to supporting investors.
- Class Action Deadline: Faruq & Faruqi reminds investors that the deadline to seek lead plaintiff status in the federal securities class action against Nektar is May 5, 2026, highlighting the importance of timely action to safeguard legal rights.
- Role of Securities Law Firm: As a leading national securities law firm, the investigation by Faruq & Faruqi suggests that Nektar may face legal challenges, which could impact its stock price and market confidence, prompting investors to stay alert for further developments.
See More
Class Action Reminder for Nektar Therapeutics Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that a class action has been filed, alleging the company failed to disclose the true prospects of the REZOLVE-AA trial, potentially leading to investor losses.
- Trial Issues: The complaint states that Nektar did not follow applicable instructions and protocol standards in the REZOLVE-AA trial, resulting in an overstated integrity and prospects of the trial, which undermines investor confidence in the company's future.
- Stock Price Impact: On December 16, 2025, Nektar announced that the REZOLVE-AA trial failed to achieve statistical significance, causing its stock price to drop by $4.14, or 7.77%, closing at $49.16 per share, reflecting market disappointment in the company's outlook.
- Investor Action: Robbins LLP encourages shareholders to participate in the class action, where lead plaintiffs can represent other members in the litigation, and investors do not need to participate in the case to be eligible for recovery, highlighting potential governance issues within the company.
See More
Nektar Therapeutics to Announce Q4 Earnings on March 12
- Earnings Announcement Schedule: Nektar Therapeutics is set to announce its Q4 earnings on March 12 after market close, with consensus EPS estimate at -$2.47 and revenue estimate at $10.41 million, reflecting a significant 64.3% year-over-year decline, indicating substantial revenue pressure on the company.
- Historical Performance Review: Over the past two years, Nektar has only beaten EPS estimates 38% of the time and revenue estimates 63% of the time, highlighting considerable volatility in its performance and suggesting that investors should approach future results with caution.
- Estimate Revision Status: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, with revenue estimates also seeing no upward revisions and one downward revision, indicating a lack of confidence in the company's future profitability.
- Financing Activities: Nektar recently completed a $400 million stock offering, and its stock surged following a $300 million equity offering, reflecting a positive market response to its financing activities, although its overall financial health remains a concern.
See More
Nektar Therapeutics Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: A shareholder has filed a class action lawsuit on behalf of investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, alleging misrepresentations regarding the Phase 2b trial for REZOLVE-AA, which may have led to investor losses.
- Lawsuit Details Revealed: The lawsuit, initiated by Bernstein Liebhard LLP, requires investors wishing to serve as lead plaintiffs to file necessary documents by May 5, 2026, indicating their representative status in the litigation.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, showcasing its significant influence in the legal field.
- Transparent Fee Structure: All representation in this lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses, ensuring minimal financial burden for all investors participating in the litigation.
See More
